The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume 128, Issue 3, Pages 290-298
Publisher
Informa UK Limited
Online
2016-01-29
DOI
10.1080/00325481.2016.1147926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal effects of canagliflozin in type 2 diabetes mellitus
- (2015) Vlado Perkovic et al. CURRENT MEDICAL RESEARCH AND OPINION
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
- (2015) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
- (2015) S. Sha et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes
- (2015) Petter Bjornstad et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Study of the Decline in Renal Function in Healthy Subjects
- (2015) Mika Baba et al. PLoS One
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
- (2014) Hala Yamout et al. AMERICAN JOURNAL OF NEPHROLOGY
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- SGLT-2 inhibition in patients with kidney disease
- (2014) R.E. Gilbert DIABETES & METABOLISM
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Empagliflozin for the treatment of type 2 diabetes
- (2014) Vidhya Jahagirdar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus
- (2014) Matthew R. Weir et al. Journal of Clinical Hypertension
- The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
- (2014) John P.H. Wilding METABOLISM-CLINICAL AND EXPERIMENTAL
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results
- (2014) Keith Usiskin et al. POSTGRADUATE MEDICINE
- Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Alan Sinclair et al. BMC Endocrine Disorders
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
- (2014) Janet B. McGill Diabetes Therapy
- Dapagliflozin in patients with type 2 diabetes mellitus
- (2014) Theodosios D. Filippatos et al. Therapeutic Advances in Endocrinology and Metabolism
- Renal effects of dapagliflozin in patients with type 2 diabetes
- (2014) Merlin C. Thomas Therapeutic Advances in Endocrinology and Metabolism
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
- (2013) Kaj Stenlöf et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
- (2013) Guntram Schernthaner et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- (2013) J. P. H. Wilding et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2013) Tim Heise et al. Diabetes Therapy
- Inflammation and the pathogenesis of diabetic nephropathy
- (2012) Jun Wada et al. CLINICAL SCIENCE
- Sodium glucose cotransporter 2 and the diabetic kidney
- (2012) Muralikrishna Gangadharan Komala et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension
- (2012) P. Palatini NEPHROLOGY DIALYSIS TRANSPLANTATION
- Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
- (2011) K. J. Lipska et al. DIABETES CARE
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
- (2011) Ian H. de Boer JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Renal glucose reabsorption inhibitors to treat diabetes
- (2011) Clifford J. Bailey TRENDS IN PHARMACOLOGICAL SCIENCES
- Risk Factors for End-Stage Renal Disease
- (2009) Chi-yuan Hsu et al. ARCHIVES OF INTERNAL MEDICINE
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
- (2009) George L. Bakris et al. KIDNEY INTERNATIONAL
- The Role of Inflammatory Cytokines in Diabetic Nephropathy
- (2008) J. F. Navarro-Gonzalez et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- SLC2A9 Is a High-Capacity Urate Transporter in Humans
- (2008) Mark J Caulfield et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More